Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs Bristol-Myers Squibb Co — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $23.52, while Bristol-Myers Squibb Co trades at $58.4 (market cap $116.30B). The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| BITQ | BMY | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $62.37 |
52-Week Low | $16.74 | $42.60 |
Market Cap | — | $116.30B |
Enterprise Value | — | $152.24B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $23.18, down 3.13% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators show neutral conditions. Support levels cluster around $23-24 while resistance sits at $25-26. Recent news highlights investor rotation away from crypto-related ETFs as Bitcoin prices decline, creating headwinds for BITQ's performance.
The outlook remains cautious given the bearish technical setup and sector-specific challenges. Investment opportunity exists for contrarian investors betting on crypto market recovery, but risks include continued ETF outflows and regulatory uncertainty. The stock's performance remains tightly correlated with broader cryptocurrency sentiment rather than standalone fundamentals.
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
